Paratek Pharmaceuticals Inc (NASDAQ:PRTK) CEO Evan Loh sold 16,265 shares of Paratek Pharmaceuticals stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $3.98, for a total value of $64,734.70. Following the completion of the transaction, the chief executive officer now directly owns 413,935 shares in the company, valued at approximately $1,647,461.30. The sale was disclosed in a document filed with the SEC, which is available at this link.
PRTK traded up $0.05 during trading on Monday, reaching $3.97. The company had a trading volume of 187,317 shares, compared to its average volume of 350,070. The company has a debt-to-equity ratio of 14.48, a quick ratio of 11.83 and a current ratio of 12.17. Paratek Pharmaceuticals Inc has a 12-month low of $2.87 and a 12-month high of $11.57. The firm’s 50-day simple moving average is $4.26 and its 200 day simple moving average is $4.43. The company has a market cap of $127.52 million, a price-to-earnings ratio of -1.11 and a beta of 1.76.
Paratek Pharmaceuticals (NASDAQ:PRTK) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($1.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.14. Paratek Pharmaceuticals had a negative return on equity of 459.96% and a negative net margin of 597.22%. The company had revenue of $2.05 million for the quarter, compared to analysts’ expectations of $1.86 million. On average, sell-side analysts expect that Paratek Pharmaceuticals Inc will post -4.32 EPS for the current year.
A number of equities analysts recently weighed in on the company. ValuEngine raised Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research raised Paratek Pharmaceuticals from a “sell” rating to a “hold” rating and set a $4.75 price target on the stock in a research note on Friday, August 9th. Finally, HC Wainwright set a $27.00 price target on Paratek Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, September 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. Paratek Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $17.35.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Recommended Story: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.